By Hilary Rosselot
Did you know Zynerba Pharmaceuticals’ RECONNECT trial has a completely at-home/virtual option for participation?
Families can participate in the RECONNECT trial completely from their home through a combination of at-home and virtual visits! The at-home option was introduced to help lessen potential barriers for families who live far from a Fragile X clinical study site or find it too challenging to go to a site for study visits.
To date, several families have enrolled in the RECONNECT trial using the at-home/virtual option. Many are not near a trial site and have appreciated the flexibility and convenience of this participation option. Families who have had significant challenges going to a clinic for visits have also been able to enroll.
At-home and virtual visits are supported by Dr. David Kudrow and his team at Science 37.
Whether you choose for your child to participate through this new at-home option or at a Fragile X clinical study site, your participation is critical to help complete the RECONNECT trial. RECONNECT is evaluating an investigational medicine in the treatment of behavioral symptoms of Fragile X syndrome. If the data is positive, it may lead to the approval of the first medicine specifically for the treatment of behavioral symptoms in Fragile X syndrome.
Interested? Learn more about the RECONNECT trial by visiting: https://fragilex.org/opportunities-for-families/reconnect/
about
Hilary Rosselot
Hilary joined the NFXF team in 2019. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for over five years. She has experience as a clinical research coordinator across many types of clinical trials and served as the clinical research manager for the Cincinnati program. She earned a bachelor’s degree in psychology, a master’s, and is a SOCRA certified clinical research professional (CCRP). She enjoys time with family and friends, a great book, a strong cup of coffee and, of course, a good laugh!
learn more
Visit the RECONNECT MyFXReserach post for more infromation:
Clinical Trial RECONNECT: ZYN002 Gel | MyFXResearch Portal (fragilex.org)
Why is the RECONNECT trial with ZYN002 Being Conducted in Fragile X Syndrome?
Zynerba Pharmaceuticals shares why the RECONNECT trial with ZYN002 is being conducted in Fragile X syndrome
The Impact of the COVID-19 Pandemic on School-Aged Children with Fragile X Syndrome
The pandemic caused by the spread of the coronavirus disease (COVID-19), beginning in early 2020, had an impact beyond anything experienced in recent history. It is important to understand how this pandemic era has impacted school-aged children with FXS so that we may continue to successfully navigate the changes that come with living through a pandemic and to understand what we can improve in the case of a future pandemic.